BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...cells and xenogeneic organs to treat cancer and organ failure.Versant-backed Tempest in reverse mergerOncology company Tempest Therapeutics Inc....
...E2PPARα – Peroxisome proliferation activated receptorα BC Staff Zavegepant (BHV-3500) Qihan Biotechnology Inc. Biohaven Pharmaceutical Holding Co. Ltd. Royalty Pharma plc LianBio Tempest Therapeutics Inc. SomaLogic...
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...Aduro Biotech Inc., where he was VP CMC technical operations.Sam Whiting joined San Francisco-based immunotherapy company Tempest Therapeutics Inc....
...He was VP, hematology and oncology at ArQule Inc. Danielle Golovin NantKwest Inc. Seres Therapeutics Inc. SQZ Biotechnologies Co. AM-Pharma B.V. Tempest Therapeutics Inc....
BioCentury | Sep 5, 2019
Financial News

Quan doubles down with new $250M fund

...companies so far this year. It co-led a tranched $70 million series B round for Tempest Therapeutics Inc....
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

...Several companies are investigating ways to convert M2 macrophages into their M1 counterparts. At AACR, Tempest Therapeutics Inc....
...New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Second Genome Inc., South San Francisco, Calif. Tempest Therapeutics Inc....
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

...M1 phenotype (see “Figure: Immune Repolarization via PPAR Alpha”). Figure: Immune repolarization via PPAR alpha Tempest Therapeutics Inc....
...cells, M1 macrophages and activated dendritic cells promote antitumor immunity in the inflamed TME. Source: Tempest Therapeutics Inc....
...NASDAQ:INCY), Wilmington, Del. Medigene AG (Xetra:MDG1), Martinsried, Germany Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Tempest Therapeutics Inc....
BioCentury | Nov 14, 2018
Preclinical News

Tempest data provide POC for PPAR alpha’s role in cancer

...New data from immuno-oncology company Tempest Therapeutics Inc. (San Francisco, Calif.) provide preclinical proof of concept that the...
...I/Ib trial in solid tumors early next year (see “Versant Launches Tempest with $70M” ). Lauren Martz TPST-1120 Tempest Therapeutics Inc. Versant...
BioCentury | Nov 2, 2018
Finance

Bye-bye, build-to-buy

...for earlier stage assets,” he said. Inception has already disclosed two stand-alone companies: cancer company Tempest Therapeutics Inc....
BioCentury | Sep 5, 2018
Company News

Management tracks: Agios, Radius

...Vaughn Embro-Pantalony, who is president of life science consulting company StratPath Management Inc. Immuno-oncology company Tempest Therapeutics Inc....
BioCentury | Jun 28, 2018
Distillery Therapeutics

Endocrine/Metabolic

...NewLink also has NLG802, a prodrug of indoximod, in Phase I testing for solid tumors. Tempest Therapeutics Inc....
BioCentury | Mar 30, 2018
Financial News

Versant launches Tempest with $70M

...Immuno-oncology company Tempest Therapeutics Inc. (San Francisco, Calif.) emerged from Versant Ventures' Inception Sciences Inc. incubator on March...
...Woiwode, F-Prime's Robert Weisskoff and Quan's Stella Xu joined Tempest's board. Tempest Therapeutics Inc., San Francisco, Calif. Virginia Li Tempest Therapeutics Inc. Indoleamine...
Items per page:
1 - 10 of 12
BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...cells and xenogeneic organs to treat cancer and organ failure.Versant-backed Tempest in reverse mergerOncology company Tempest Therapeutics Inc....
...E2PPARα – Peroxisome proliferation activated receptorα BC Staff Zavegepant (BHV-3500) Qihan Biotechnology Inc. Biohaven Pharmaceutical Holding Co. Ltd. Royalty Pharma plc LianBio Tempest Therapeutics Inc. SomaLogic...
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...Aduro Biotech Inc., where he was VP CMC technical operations.Sam Whiting joined San Francisco-based immunotherapy company Tempest Therapeutics Inc....
...He was VP, hematology and oncology at ArQule Inc. Danielle Golovin NantKwest Inc. Seres Therapeutics Inc. SQZ Biotechnologies Co. AM-Pharma B.V. Tempest Therapeutics Inc....
BioCentury | Sep 5, 2019
Financial News

Quan doubles down with new $250M fund

...companies so far this year. It co-led a tranched $70 million series B round for Tempest Therapeutics Inc....
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

...Several companies are investigating ways to convert M2 macrophages into their M1 counterparts. At AACR, Tempest Therapeutics Inc....
...New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Second Genome Inc., South San Francisco, Calif. Tempest Therapeutics Inc....
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

...M1 phenotype (see “Figure: Immune Repolarization via PPAR Alpha”). Figure: Immune repolarization via PPAR alpha Tempest Therapeutics Inc....
...cells, M1 macrophages and activated dendritic cells promote antitumor immunity in the inflamed TME. Source: Tempest Therapeutics Inc....
...NASDAQ:INCY), Wilmington, Del. Medigene AG (Xetra:MDG1), Martinsried, Germany Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Tempest Therapeutics Inc....
BioCentury | Nov 14, 2018
Preclinical News

Tempest data provide POC for PPAR alpha’s role in cancer

...New data from immuno-oncology company Tempest Therapeutics Inc. (San Francisco, Calif.) provide preclinical proof of concept that the...
...I/Ib trial in solid tumors early next year (see “Versant Launches Tempest with $70M” ). Lauren Martz TPST-1120 Tempest Therapeutics Inc. Versant...
BioCentury | Nov 2, 2018
Finance

Bye-bye, build-to-buy

...for earlier stage assets,” he said. Inception has already disclosed two stand-alone companies: cancer company Tempest Therapeutics Inc....
BioCentury | Sep 5, 2018
Company News

Management tracks: Agios, Radius

...Vaughn Embro-Pantalony, who is president of life science consulting company StratPath Management Inc. Immuno-oncology company Tempest Therapeutics Inc....
BioCentury | Jun 28, 2018
Distillery Therapeutics

Endocrine/Metabolic

...NewLink also has NLG802, a prodrug of indoximod, in Phase I testing for solid tumors. Tempest Therapeutics Inc....
BioCentury | Mar 30, 2018
Financial News

Versant launches Tempest with $70M

...Immuno-oncology company Tempest Therapeutics Inc. (San Francisco, Calif.) emerged from Versant Ventures' Inception Sciences Inc. incubator on March...
...Woiwode, F-Prime's Robert Weisskoff and Quan's Stella Xu joined Tempest's board. Tempest Therapeutics Inc., San Francisco, Calif. Virginia Li Tempest Therapeutics Inc. Indoleamine...
Items per page:
1 - 10 of 12